中国新药杂志

眼科药物的药动学研究策略

PDF下载

宋硕 ¹^,² , 王若男 ¹^,² , 钱仪敏 ² , 孟永 ³ , 周璐 ³ , 李华 ²^,³

中国新药杂志 | 重大新药创制专项巡礼 2021,30(18): 1668-1674

收起

中国新药杂志 |重大新药创制专项巡礼 2021 , 30 (18) : 1668 -1674

眼科药物的药动学研究策略

全屏

宋硕¹^,², 王若男¹^,², 钱仪敏², 孟永³, 周璐³, 李华²^,³

作者信息

¹中国医药工业研究总院国家上海新药安全评价研究中心，上海　201203

²上海益诺思生物技术股份有限公司，上海　201203

³益诺思生物技术南通有限公司，南通　226133

通讯作者:

李华，男，博士，研究员，研究方向：药物毒理。联系电话：（021）60211993，E-mail：hli@ncdser.com。

作者简介:

宋硕，男，硕士研究生，研究方向：药物毒理。E-mail：SS19970301@163.com。

Pharmacokinetic research strategy of ophthalmic drugs

Shuo SONG¹^,², Ruo-nan WANG¹^,², Yi-min QIAN², Yong MENG³, Lu ZHOU³, Hua LI²^,³

Affiliations

¹National Shanghai Center for New Drug Safety Evaluation and Research of China State Institute of Pharmaceutical Industry, Shanghai 201203, China

²Shanghai InnoStar Biotech Co., Ltd., Shanghai 201203, China

³InnoStar Biotech Nantong Co., Ltd., Nantong 226133, China

出版时间: 2021-09-30

文章导航

摘要

收起

眼药动学是研究药物在眼组织中的吸收、分布、代谢和排泄的过程，并可用数学模型定量描述，相对于整体药动学更精细、复杂。眼药动学研究是眼科药物开发和指导眼科临床合理用药的关键。因此，全面了解眼药动学的研究内容对眼科药物开发人员和使用人员来说都是非常重要的。本文概述了眼药动学研究中的重点内容，方便相关眼科研究人员对眼科用药的药动学有一个整体的认识，提高眼科用药的安全性和合理性。

关键词

屏障 / 给药途径 / 眼药动学

Abstract

收起

Ocular pharmacokinetics is the process of absorption, distribution, metabolism and excretion of drugs in eye tissues, and can be quantitatively described by mathematical models, which is more sophisticated and complex than the overall pharmacokinetics. Ocular pharmacokinetics research is the key to the development of ophthalmic drugs and to guide the rational use of ophthalmic drugs. Therefore, a comprehensive understanding of the research content of ocular pharmacokinetics is very important for ophthalmic drugs developers and users. This article outlines the key content of ocular pharmacokinetic research, so that relevant ophthalmologists can have an overall understanding of the pharmacokinetics of ophthalmic drugs, and improve the safety and rationality of ophthalmic drugs.

Key words

barrier / administration route / ocular pharmacokinetics

引用本文

宋硕, 王若男, 钱仪敏, 孟永, 周璐, 李华. 眼科药物的药动学研究策略. 中国新药杂志, 2021 , 30 (18) : 1668 -1674 .

Shuo SONG, Ruo-nan WANG, Yi-min QIAN, Yong MENG, Lu ZHOU, Hua LI. Pharmacokinetic research strategy of ophthalmic drugs[J]. Chinese Journal of New Drugs, 2021 , 30 (18) : 1668 -1674 .

基金

收起

国家“重大新药创制”科技重大专项资助项目(2018ZX09201017-008)
上海市科委研发平台专项上海市科委资助项目(18DZ2290100)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

YELLEPEDDI VK, PALAKURTHI S. Recent advances in topical ocular drug delivery[J]. J Ocul Pharmacol Ther, 2016, 32(2): 67-82.

[2]

AGRAHARI V, MANDAL A, AGRAHARI V, et al. A comprehensive insight on ocular pharmacokinetics[J]. Drug Deliv Transl Res, 2016, 6(6): 735-754.

[3]

PATEL A, CHOLKAR K, AGRAHARI V, et al. Ocular drug delivery systems: an overview[J]. World J Pharmacol, 2013, 2(2): 47-64.

[4]

DUBALD M, BOURGEOIS S, ANDRIEU V, et al. Ophthalmic drug delivery systems for antibiotherapy—a review[J]. Pharmaceutics, 2018, 10(1): 10.

[5]

ACHOURI D, ALHANOUT K, PICCERELLE P, et al. Recent advances in ocular drug delivery[J]. Drug Dev Ind Pharm, 2013, 39(11): 1599-1617.

[6]

DUMOUCHEL JL, CHEMUTURI N, MILTON MN, et al. Models and approaches describing the metabolism, transport, and toxicity of drugs administered by the ocular route[J]. Drug Metab Dispos, 2018, 46(11): 1670-1683.

[7]

RIMPELÄ AK, REINISALO M, HELLINEN L, et al. Implications of melanin binding in ocular drug delivery[J]. Adv Drug Deliv Rev, 2018, 126: 23-43.

[8]

CARVALHO IM, MARQUES CS, OLIVEIRA RS, et al. Sustained drug release by contact lenses for Glaucoma treatment-A review[J]. J Control Release, 2015, 202: 76-82.

[9]

NAYAK K, MISRA M. A review on recent drug delivery systems for posterior segment of eye[J]. Biomed Pharmacother, 2018, 107: 1564-1582.

[10]

JOHNSON KS, CHU DS. Evaluation of sub-Tenon triamcinolone acetonide injections in the treatment of scleritis[J]. Am J Ophthalmol, 2010, 149(1): 77-81.

[11]

MANDAL A, BISHT R, RUPENTHAL I, et al. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies[J]. J Control Release, 2017, 248: 96-116.

[12]

MISSEL P, SARANGAPANI R. Physiologically based ocular pharmacokinetic modeling using computational methods[J]. Drug Discov Today, 2019, 24(8): 1551-1563.

[13]

NIXON GJ. Clinical Ocular Pharmacology (5th ed.)[J]. Clin Exp Optom, 2008, 91(6): 575-576.

[14]

PARK SJ, CHOI Y, NA YM, et al. Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model[J]. Invest Ophthalmol Vis Sci, 2016, 57(6): 2612-2617.

[15]

HUTTON-SMITH LA, GAFFNEY EA, BYRNE HM, et al. Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic/pharmacodynamic model[J]. Mol Pharm, 2018, 15(7): 2770-2784.

[16]

DJEBLI N, KHIER S, GRIGUER F, et al. Ocular drug distribution after topical administration: population pharmacokinetic model in rabbits[J]. Eur J Drug Metab Pharmacokinet, 2017, 42(1): 59-68.

[17]

ELLISON CA. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation[J]. Regul Toxicol Pharmacol, 2018, 99: 61-77.

[18]

DEL AMO EM, URTTI A. Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data[J]. Exp Eye Res, 2015, 137: 111-124.

[19]

ROBINSON ML. Animal models in eye research[J]. Hum Genomics, 2009, 3(4): 381-382.

[20]

OZCIMEN M, SAKARYA Y, OZCIMEN S, et al. Pharmacokinetics of intravenously administered tigecycline in eye compartments: an experimental study[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(12): 1993-1997.

[21]

CASTRO-BALADO A, MONDELO-GARCÍA C, GONZÁLEZ-BARCIA M, et al. Ocular biodistribution studies using molecular imaging[J]. Pharmaceutics, 2019, 11(5): 237.

[22]

KOSTEWICZ ES, ABRAHAMSSON B, BREWSTER M, et al. In vitro models for the prediction of in vivo performance of oral dosage forms[J]. Eur J Pharm Sci, 2014, 57: 342-366.

[23]

JIANG W, KIM S, ZHANG X, et al. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation[J]. Int J Pharm, 2011, 418(2): 151-160.

[24]

DENG F, RANTA VP, KIDRON H, et al. General pharmacokinetic model for topically administered ocular drug dosage forms[J]. Pharm Res, 2016, 33(11): 2680-2690.

[25]

KOVACS K, WAGLEY S, QUIRK MT, et al. Pharmacokinetic study of vitreous and serum concentrations of triamcinolone acetonide after posterior sub-tenon's injection[J]. Am J Ophthalmol, 2012, 153(5): 939-948.

[26]

GUKASYAN HJ, HAILU S, KARAMI TK, et al. Ocular biopharmaceutics: impact of modeling and simulation on topical ophthalmic formulation development[J]. Drug Discov Today, 2019, 24(8): 1587-1597.

[27]

VAN GESTEL A, SEVERENS JL, WEBERS CA, et al. Modeling complex treatment strategies: construction and validation of a discrete event simulation model for Glaucoma[J]. Value Health, 2010, 13(4): 358-367.

[28]

武峰, 赵秀丽. 滴眼剂人眼部药代动力学研究的方法学探讨[J]. 中国临床药理学杂志, 2015, 31(5): 395-397.

[29]

HUANG D, CHEN YS, RUPENTHAL ID. Overcoming ocular drug delivery barriers through the use of physical forces[J]. Adv Drug Deliv Rev, 2018, 126: 96-112.

[30]

DURAIRAJ C. Ocular pharmacokinetics[J]. Handb Exp Pharmacol, 2017, 242: 31-55.

[31]

WANG L, SYN N, LI S, et al. The penetration and distribution of topical atropine in animal ocular tissues[J]. Acta Ophthalmol, 2019, 97(2): e238-e247.

[32]

SCHOPF L, ENLOW E, POPOV A, et al. Ocular pharmacokinetics of a novel loteprednol etabonate 0.4% ophthalmic formulation[J]. Ophthalmol Ther, 2014, 3(1-2): 63-72.

[33]

WEN ZY, MURATOMI N, HUANG W, et al. The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery[J]. Int J Pharm, 2019, 557: 273-279.

[34]

DEL AMO EM, URTTI A. Rabbit as an animal model for intravitreal pharmacokinetics: Clinical predictability and quality of the published data[J]. Exp Eye Res, 2015, 137: 111-124.

[35]

RAMSAY E, HAGSTRÖM M, VELLONEN K, et al. Role of retinal pigment epithelium permeability in drug transfer between posterior eye segment and systemic blood circulation[J]. Eur J Pharm Biopharm, 2019, 143: 18-23.

2021年第30卷第18期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-30
出版时间：2021-09-30

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-06-21

基金

国家“重大新药创制”科技重大专项资助项目(2018ZX09201017-008)

上海市科委研发平台专项上海市科委资助项目(18DZ2290100)

作者信息

¹中国医药工业研究总院国家上海新药安全评价研究中心，上海　201203

²上海益诺思生物技术股份有限公司，上海　201203

³益诺思生物技术南通有限公司，南通　226133

通讯作者:

李华，男，博士，研究员，研究方向：药物毒理。联系电话：（021）60211993，E-mail：hli@ncdser.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322906793936028242

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT